Phenylephrine

Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Efficacy and Safety of its MAP™ Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasis

Retrieved on: 
Wednesday, March 17, 2021
Science, Research, Pharmaceutical, Optical, Health, FDA, Medical devices, Clinical trials, Health, Drugs, Chemical compounds, Disability, Muscarinic antagonists, Pyridines, Tropicamide, Phenols, Phenylephrine, Mydriasis, Near-sightedness, Presbyopia

Adverse events with tropicamide-phenylephrine were infrequent at 3% and mild with fewer than 1% of patients reporting blurred vision, reduced acuity, photophobia or instillation site pain.

Key Points: 
  • Adverse events with tropicamide-phenylephrine were infrequent at 3% and mild with fewer than 1% of patients reporting blurred vision, reduced acuity, photophobia or instillation site pain.
  • This publication follows the U.S. Food and Drug Administrations recent acceptance of Eyenovias New Drug Application (NDA) for MydCombi, the micro-dosed fixed-combination tropicamide-phenylephrine agent evaluated in these pivotal studies.
  • Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics.
  • Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis.

Mydriasert: An Ophthalmic Insert Containing 0.28mg Tropicamide and 5.4mg Phenylephrine Hydrochloride - Global Drug Insight and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 9, 2021
Pharmaceutical, Health, Optical, Chemical compounds, Drugs, Vasoconstrictors, Phenols, Organic compounds, Pyridines, Tropicamide, Phenylephrine, Ophthalmic, Conjunctiva, SWOT analysis

The "Mydriasert - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mydriasert - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views.
  • Mydriasert is an ophthalmic insert containing 0.28mg tropicamide and 5.4mg phenylephrine hydrochloride.
  • It is an ophthalmic pellet inserted into the lower conjunctival fornix prior to surgery or diagnostic procedure.

Global Phenylephrine Market to 2025 - by Manufacturers, Regions, Technology and Application

Retrieved on: 
Wednesday, December 30, 2020
Pharmaceutical companies, Business, Companies, Profit, Financial ratios, Amines, Phenols, Phenylephrine, Hikma Pharmaceuticals, Gross margin, Amneal Pharmaceuticals, Revenue

16.2.4 Alcon Laboratories Phenylephrine Sales, Revenue, Price and Gross Margin (2015-2020)

Key Points: 
  • 16.2.4 Alcon Laboratories Phenylephrine Sales, Revenue, Price and Gross Margin (2015-2020)
    16.5.4 Paragon BioTeck Phenylephrine Sales, Revenue, Price and Gross Margin (2015-2020)
    16.6.4 West-Ward Pharmaceuticals Phenylephrine Sales, Revenue, Price and Gross Margin (2015-2020)
    16.9.4 Par Sterile Products Phenylephrine Sales, Revenue, Price and Gross Margin (2015-2020)
    16.11.4 Fresenius Kabi Phenylephrine Sales, Revenue, Price and Gross Margin (2015-2020)
    16.12.4 Amneal Pharmaceuticals Phenylephrine Sales, Revenue, Price and Gross Margin (2015-2020)
    16.13.4 Vintage Labs Phenylephrine Sales, Revenue, Price and Gross Margin (2015-2020)
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Worldwide Industry for Phenylephrine to 2025 - Featuring Pfizer, Alcon Laboratories and Perrigo Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, December 21, 2020
Health, Pharmaceutical, ASEAN, Southeast Asia, Compound annual growth rate, Phenylephrine, Chemical compounds, Medical specialties, Organ systems

This report describes the global market size of Phenylephrine from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025.

Key Points: 
  • This report describes the global market size of Phenylephrine from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025.
  • For the geography segment, regional supply, demand, major players, price is presented from 2015 to 2025.
  • The key countries for each region are also included such as the United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.
  • For the competitor segment, the report includes global key players of Phenylephrine as well as some small players.

Omeros Participates in Investor Conference Focused on COVID-19 Therapeutics in Development

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, General Health, Infectious diseases, Health, Pharmaceutical, Amines, Phenethylamines, Phenols, Phenylephrine, Chemical compounds, Coronavirus disease, Medical specialties, Organ systems

Omeros previously announced positive results from the treatment with narsoplimab of six critically ill COVID-19 patients under a compassionate use protocol in Bergamo, Italy.

Key Points: 
  • Omeros previously announced positive results from the treatment with narsoplimab of six critically ill COVID-19 patients under a compassionate use protocol in Bergamo, Italy.
  • All patients initially required mechanical ventilation and, following treatment with narsoplimab, all recovered, survived and were discharged from the hospital.
  • Five to six months following discharge, none of the patients showed any clinical or laboratory evidence of longer-term effects from COVID-19.
  • In addition to its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple late-stage clinical development programs focused on complement-mediated disorders, including COVID-19, and substance abuse.

Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting

Retrieved on: 
Monday, October 5, 2020
Health, Other Health, General Health, Clinical trials, Pharmaceutical, Optical, Biotechnology, RTT, Drugs, Muscarinic antagonists, Psychoactive drugs, Chemical compounds, Phenols, Pyridines, Tropicamide, Atropine, Phenylephrine, Optometry, Near-sightedness

Siddarth Rathi and April Jasper will present the latest analyses and updates from the companys clinical studies at the American Academy of Optometry Academy 2020 At Home Con .

Key Points: 
  • Siddarth Rathi and April Jasper will present the latest analyses and updates from the companys clinical studies at the American Academy of Optometry Academy 2020 At Home Con .
  • Clinical results will cover Pupil Dilation Speed with MAP Fixed Combination (FC) Tropicamide 1% Phenylephrine 2.5% (TR-PH)-Ophthalmic Solution.
  • Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics.
  • MicroPine (atropine ophthalmic solution) is being evaluated in the CHAPERONE Phase 3 clinical study for reduction in pediatric myopia progression.

Omeros Corporation Reports Third Quarter 2019 Financial Results

Retrieved on: 
Tuesday, November 12, 2019
Biotechnology, Pharmaceutical, Health, Oncology, Chemical compounds, RTT, Organic compounds, Medical specialties, Asset, Cash, Cash and cash equivalents, Ketorolac, Phenylephrine, Omeros

3Q 2019 revenues were $29.9 million, another quarter of record sales of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%.

Key Points: 
  • 3Q 2019 revenues were $29.9 million, another quarter of record sales of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%.
  • At September 30, 2019, Omeros had cash, cash equivalents and short-term investments available for operations of $27.3 million, a decrease of $4.5 million from June 30, 2019.
  • As of September 30, 2019, Omeros had $27.3 million of cash, cash equivalents and short-term investments available for operations, a decrease of $4.5 million from June 30, 2019.
  • Omeros management will host a conference call to discuss the financial results and to provide an update on business activities.

Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection

Retrieved on: 
Tuesday, October 22, 2019
Chemical compounds, Chemistry, RTT, Phenols, Health sciences, Phenethylamines, Amines, Phenylephrine, Compounding, Medication, Pharmacy

Prior to the FDA approval of Biorphen, phenylephrine injection was only approved and available as a highly concentrated formulation that required hospitals to manually dilute the concentrate prior to administration, or purchase ready-to-use formulations from 503B compounding pharmacies.

Key Points: 
  • Prior to the FDA approval of Biorphen, phenylephrine injection was only approved and available as a highly concentrated formulation that required hospitals to manually dilute the concentrate prior to administration, or purchase ready-to-use formulations from 503B compounding pharmacies.
  • Compounded drugs do not have to undergo FDA premarket review for safety, effectiveness and certain controls over manufacturing quality.
  • "The approval of Biorphen represents an important step forward in Etons commitment to improving existing medicines to address unmet patient needs.
  • BIORPHEN injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Fresenius Kabi Introduces Phenylephrine Hydrochloride Injection, USP

Retrieved on: 
Friday, August 30, 2019
Surgery, Hospitals, Biotechnology, Other Health, Pharmaceutical, Health, General Health, Drugs, Psychoactive drugs, Neurochemistry, RTT, Amines, Fresenius, Societates Europaeae, Phenylephrine, Ketamine, Phenylephrine Hydrochloride Injection, USP, Fresenius Kabi

Fresenius Kabi announced today the immediate availability in the United States of Phenylephrine Hydrochloride Injection, USP.

Key Points: 
  • Fresenius Kabi announced today the immediate availability in the United States of Phenylephrine Hydrochloride Injection, USP.
  • (Photo: Business Wire)
    Fresenius Kabi Phenylephrine Hydrochloride Injection, USP is available as a 1 mL single dose vial and as 5 mL and 10 mL pharmacy bulk packages.
  • Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
  • Fresenius Kabi is pleased to expand our anesthesia and analgesia portfolio with these three presentations of Phenylephrine Hydrochloride Injection, said John Ducker, president and CEO of Fresenius Kabi USA.

Nephron Pharmaceuticals Corporation Leverages the GHX Exchange Platform for Simplified Product Ordering

Retrieved on: 
Monday, April 29, 2019
Chemical compounds, Alcohols, RTT, Drugs, Computing, Phenethylamines, Phenylephrine, Vasoconstrictors, Nephron, Electronic data interchange, Labetalol, Bicarbonate

WEST COLUMBIA, S.C., April 29, 2019 /PRNewswire/ --Nephron Pharmaceuticals Corporation initiated Electronic Data Interchange (EDI) ordering through the Global Healthcare Exchange, LLC (GHX) platform, accessible immediately.

Key Points: 
  • WEST COLUMBIA, S.C., April 29, 2019 /PRNewswire/ --Nephron Pharmaceuticals Corporation initiated Electronic Data Interchange (EDI) ordering through the Global Healthcare Exchange, LLC (GHX) platform, accessible immediately.
  • This platform enables purchasers to select products from multiple vendors in one place, rather than logging in to the Nephron online ordering system.
  • Utilizing the GHX cloud-based platform helps to reduce manual work and provides real-time data to view and validate order information.
  • Nephron products including Sodium Bicarbonate, Phenylephrine, Labetalol and more are available for purchase through the GHX platform.